MFAM
VRDN icon

Motley Fool Asset Management’s Viridian Therapeutics VRDN Stock Holding History

Motley Fool Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-11,792
Closed -$363K – 174
2019
Q2 		$363K Buy
11,792
+192
+2% +$7.71K 0.04% 153
2019
Q1 		$485K Buy
11,600
+1,917
+20% +$86.7K 0.06% 138
2018
Q4 		$440K Buy
+9,683
New +$560K 0.06% 132

Other funds holding VRDN

AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Motley Fool Asset Management's VRDN Position: Q3 2019 in Review

Motley Fool Asset Management sold out of Viridian Therapeutics (VRDN) in Q3 2019, closing a stake of 11,792 shares — an estimated $363K sold.

Motley Fool Asset Management first reported a position in VRDN in Q4 2018 and held it in 3 quarters. The position peaked at $485K in Q1 2019. 33 funds tracked by Wall St. Rank hold VRDN as of Q3 2019.

  • Motley Fool Asset Management reported no remaining Viridian Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Motley Fool Asset Management sold 11,792 Viridian Therapeutics shares in Q3 2019, an estimated $363K.
  • Motley Fool Asset Management first reported a position in Viridian Therapeutics in Q4 2018 and held it in 3 quarters.
  • Motley Fool Asset Management's Viridian Therapeutics position peaked at $485K in Q1 2019.
  • 33 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2019.

Based on Motley Fool Asset Management's 13F filing for Q3 2019, filed 12 Nov 2019.